Results 251 to 260 of about 111,593 (328)

Effectiveness and safety of the oxytocin antagonist( atosiban) versus beta-adrenergic agonists (salbutamol) in the treatment of preterm labor

, 2017
Yasamin H. Sharif Al-Shibany, Saba M. Swadi Al- Thuwainy   +1 more
openalex   +2 more sources

Established and Emerging Roles of Epigenetic Regulation in Diabetic Cardiomyopathy

Diabetes/Metabolism Research and Reviews, Volume 41, Issue 6, September 2025.
ABSTRACT An increasing number of individuals are at high risk of type 2 diabetes (T2DM) and its cardiovascular (CV) complications, which challenges healthcare systems with an increased risk of developing CV diseases. Patients with T2DM exhibit a unique cardiac phenotype termed diabetic cardiomyopathy (DCM).
Adam Russell‐Hallinan, Narainrit Karuna, Frank Lezoualc'h, Giuseppe Matullo, Hana Baker, Monique Bernard, Yvan Devaux, Lina Badimon, Gemma Vilahur, Jennifer Rieusset, Geneviève A. Derumeaux, Chris J. Watson   +11 more
wiley   +1 more source

Atypical development and swift resolution of an ulcerated hemangioma: a case report. [PDF]

J Med Case Rep
Chakhunashvili K, Kvirkvelia E, Chakhunashvili DG.   +2 more
europepmc   +1 more source

The future of pharmacogenetics in the treatment of heart failure [PDF]

, 2015
Alex S Doney, Chim C Lang, Colin N Palmer, Green SA, Helen M Parry, Lanfear DE, Levy AP, Lillvis JH, Mesquita ET, Mohamed Subhan Anwar, Morrison AC, Muhammad Zaid Iskandar   +11 more
core   +2 more sources

Recent Developments in the Optical Control of Adrenergic Signaling

Medicinal Research Reviews, Volume 45, Issue 5, Page 1307-1322, September 2025.
ABSTRACT Adrenoceptors (ARs) play a vital role in various physiological processes and are key therapeutic targets. The advent of optical control techniques, including optogenetics and photopharmacology, offers the potential to modulate AR signaling with precise temporal and spatial resolution. In this review, we summarize the latest advancements in the
Shuang Shi, Yangzhi Cao, Maikel Wijtmans, Henry F. Vischer, Rob Leurs   +4 more
wiley   +1 more source

β3‐Adrenoceptor Agonist Effects on the Urinary Bladder Beyond Detrusor Relaxation

Neurourology and Urodynamics, Volume 44, Issue 7, Page 1498-1502, September 2025.
ABSTRACT Aims β3‐Adrenoceptor agonists such as mirabegron or vibegron reach pharmacokinetic steady‐state within a few days. However, maximum improvements in symptoms of the overactive bladder syndrome are reached at time points later than 4 weeks, that is, detrusor smooth muscle relaxation cannot fully explain clinical effects.
Martin C. Michel, Ebru Arioglu‐Inan, Martin Hennenberg   +2 more
wiley   +1 more source

Visual Thinking to Explore "Relational Pharmacology": Systemic Maps for Managing Non-Selective Antidepressants in Cardiovascular Prevention. [PDF]

Pharmacy (Basel)
García-Domínguez I, Rodríguez-Luna A, Machuca M.   +2 more
europepmc   +1 more source

Differential mechanisms of action of the trace amines octopamine, synephrine and tyramine on the porcine coronary and mesenteric artery [PDF]

, 2019
Chess-Williams, Russ, Koh, Andy, Lohning, Anna Elizabeth   +2 more
core   +1 more source

The Clinical Significance of the Subtypes of Detrusor Overactivity: A Systematic Review

Neurourology and Urodynamics, Volume 44, Issue 7, Page 1484-1490, September 2025.
ABSTRACT Introduction Detrusor overactivity (DO) is the “occurrence of detrusor contraction(s) during filling cystometry” [7] and can be “phasic” or “terminal” [26]. The aim of this systematic review was to establish whether there is any clinical significance between the different subtypes of DO in terms of demographics, underlying pathophysiology ...
Manisha Teji, Nicholas Raison, Nicholas Faure‐Walker   +2 more
wiley   +1 more source

Brainstem noradrenergic modulation of the kisspeptin neuron GnRH pulse generator in mice. [PDF]

Nat Commun
Vas S, Morris PG, Gul Z, Ruiz-Cruz M, Han SY, Herbison AE.   +5 more
europepmc   +1 more source